8-K: TransCode Therapeutics CFO Departs; Interim Appointed

TransCode Therapeutics announced the departure of its CFO, Thomas A. Fitzgerald, effective September 9, 2026, with John Tattory appointed as interim CFO.

Summary

• Thomas A. Fitzgerald has resigned as Chief Financial Officer, principal financial officer, principal accounting officer, and a Director of TransCode Therapeutics, Inc., effective September 9, 2026.
• Mr. Fitzgerald's departure is not due to any disagreement with the Company.
• The Company has entered into a Separation and Transition Services Agreement with Mr. Fitzgerald.
• Under the agreement, Mr. Fitzgerald is eligible for severance payments totaling up to $1,250,000, contingent on certain funding milestones.
• Mr. Fitzgerald's outstanding equity awards will become fully vested, and his exercise period will be extended.
• He will also receive an option to purchase 185,000 shares of common stock, with vesting and exercise periods subject to acceleration based on funding.
• The Company will cover Mr. Fitzgerald's COBRA or Medicare premiums for up to 12 months.
• John Tattory has been appointed as the Interim Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective September 9, 2026, serving as a consultant.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative development due to the departure of a key executive, though the severance package and interim appointment mitigate immediate concerns.

Positives

• The departure of the CFO was not due to any disagreement with the company, indicating a potentially amicable separation.
• A comprehensive separation agreement provides Mr. Fitzgerald with significant severance ($1,250,000 potential), vested equity, and extended option terms, which can be seen as a positive retention/separation strategy.
• The company has secured an experienced interim CFO, John Tattory, who brings extensive financial leadership experience in the biotech sector.
• The severance package includes performance-based incentives tied to future funding, aligning Mr. Fitzgerald's interests with the company's success during the transition.
• The company will cover health insurance premiums for Mr. Fitzgerald for up to 12 months.

Negatives

• The departure of a key executive like the CFO can create uncertainty and disrupt ongoing operations.
• The severance package, while structured with performance incentives, represents a significant financial commitment for the company.
• The company's reliance on future funding to trigger the full severance payment highlights potential financial pressures.

Risks

• The company's ability to achieve the $5.0 million and $10.0 million Qualified Funding thresholds within the specified timeframe could impact the total severance paid to Mr. Fitzgerald.
• The transition to an interim CFO, even an experienced one, may lead to a temporary period of adjustment and potential operational inefficiencies.
• The company's financial health and ability to secure future funding are critical factors influencing the full payout of severance and the company's overall stability.

Future Outlook

The future outlook is implicitly tied to the company's ability to secure 'Qualified Funding' of at least $5.0 million and potentially $10.0 million. These funding events are critical not only for the company's operations and growth but also for determining the full extent of severance payments to the departing CFO and the acceleration of his equity awards. The appointment of an experienced interim CFO suggests a focus on maintaining financial stability during this transition.

Management Comments

• "We appreciate your contributions and would like to work with you to make this transition as smooth as possible."
• "The Company shall, if it has not already done so, pay or provide you with the Accrued Obligations described in the Employment Agreement."
• "You acknowledge and agree that your resignations described in this section shall be effective as of the date of this Agreement and shall not be subject to the Revocation Period (as defined below) or otherwise revocable."
• "You acknowledge that you consulted with an attorney before signing this Agreement."

Industry Context

StockSavvy.ai notes that executive departures, particularly CFOs, are common in the development-stage biotechnology sector, often linked to funding cycles and strategic shifts. The structure of the severance package, with performance-based tranches tied to financing, is a typical mechanism used by companies in this industry to manage cash outflows while incentivizing continued engagement or alignment with future success.

Comparison to Industry Standards

• The severance package of up to $1.25 million for a CFO departing a development-stage biotech company is within the typical range, especially when considering the inclusion of equity acceleration and extended option terms.
• The contingent nature of a significant portion of the severance, tied to achieving specific funding rounds ($5M and $10M), is a common practice in the industry to conserve cash during periods of uncertainty.
• The appointment of an interim CFO from a reputable consulting firm like Stout Risius Ross, LLC is standard practice for companies needing experienced financial leadership during executive transitions.
• The provision of health benefits (COBRA/Medicare) for up to 12 months is a common component of executive separation agreements in the US.
• The inclusion of a mutual release of claims is a standard legal protection for both the company and the departing executive in such agreements.

Management Changes

Stakeholder Impact

• Shareholders: May experience short-term uncertainty due to the CFO's departure, but the interim appointment and structured severance aim to maintain stability. The company's ability to secure funding, which impacts severance, is also a key concern for shareholders.
• Employees: The transition may lead to a period of adjustment. The company's continued focus on securing funding is crucial for employee job security.
• Creditors: The company's financial stability, influenced by its ability to secure funding and manage its obligations (including severance), is important for creditors.
• Management: The remaining management team will need to ensure a smooth transition and continued operational focus.

Next Steps

• The company must manage the transition to the interim CFO, John Tattory.
• The company needs to work towards achieving the $5.0 million and $10.0 million Qualified Funding thresholds to determine the final severance payout to Mr. Fitzgerald.
• The company is expected to register Mr. Fitzgerald's granted stock option on a Form S-8 registration statement by December 31, 2026.
• Mr. Fitzgerald is expected to provide transitional services to the company.

Key Dates

Recommendation

The departure of a CFO is a significant event, but the filing indicates an amicable separation with a structured severance package and an experienced interim replacement. The key determinant for future performance and stock price will be the company's ability to secure necessary funding, which is also linked to the severance payout. Without clear operational or financial performance updates, a 'hold' recommendation is prudent, pending further clarity on funding and strategic execution.

Keywords

CFO resignation, Interim CFO appointment, Severance agreement, Equity awards, Funding milestones, Transition services, Corporate governance, Executive departure